Fluticasone propionate

Viatris Inc. navigates a competitive landscape with improved financial performance, driven by new product launches like Breyna and Wixela. The company aims for a 3.0x leverage ratio by 2024, with analysts projecting FY2024 EPS at $2.72 and FY2025 at $2.57. Debt reduction and strategic divestitures enhance financial flexibility, but pricing pressures and competitive challenges persist.

Abingworth seeks to raise up to $1.5 billion for biopharma clinical development in return for royalties, aiming to support up to eight late-stage trials. This follows earlier deals with Gilead and Teva, where Abingworth funded clinical studies in exchange for fixed payments and royalties on sales.

Indian stock market recovered on November 29, with Nifty 50 and Sensex gaining 0.91% and 0.96%, respectively, driven by heavyweights like Bharti Airtel and Reliance Industries. Despite this, both indices ended November with a drop of up to 0.5%. Nifty Pharma was the top sectoral performer, while Nifty Realty and Nifty PSU Bank lagged. Adani Group stocks rallied for the third consecutive session, with Adani Green Energy and Adani Energy Solutions leading gains.

Role of viral respiratory infections in asthma and asthma exacerbations, airflow obstruction associated with increased smooth muscle extracellular matrix, asthma therapy and airway remodeling, biologics and airway remodeling in severe asthma, phenotype- and patient-specific modeling in asthma, prostaglandin D2 receptor 2 pathway in asthma, prostaglandin D2-induced bronchoconstriction, prostaglandin D2 pathway upregulation in relation to asthma severity, CRTH2 antagonism reducing allergen-induced airway responses, DP2 antagonism reducing airway smooth muscle mass, fevipiprant efficacy in reducing exacerbations in severe asthma, DP2 antagonist GB001 for asthma, PGD2/DP2 receptor activation promoting severe viral bronchiolitis, increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in asthmatic airway epithelium, effects of topical corticosteroids on eicosanoid release by airway epithelial cells, glucocorticoid-regulated inflammatory cyclooxygenase, aeroallergen-induced IL-33 predisposing to respiratory virus-induced asthma, targeting P2Y13 receptor suppressing IL-33 and HMGB1 release, chronic IL-33 expression predisposing to virus-induced asthma exacerbations, viral infections and atopy in asthma pathogenesis, DP1 prostanoid receptor activation increasing severity of acute lower respiratory viral infection, virus-induced inflammasome activation suppressed by prostaglandin D2/DP1 signaling, airway hyperresponsiveness and inflammation in mild asthma, airway remodeling-associated mediators in moderate to severe asthma, transforming growth factor β1 function in airway remodeling, anti-IL-5 treatment reducing ECM protein deposition, effects of influenza on alveolar macrophage viability, macrophage polarization and allergic asthma, CRTH2 antagonism effect on rhinovirus infection response, expression of c-erbB receptors and ligands in asthmatic bronchial epithelium, epidermal growth factor receptor involvement in epithelial repair, epithelial damage and response in asthma, cluster analysis of nasal cytokines during rhinovirus infection, proteins associated with airway fibrosis in allergic asthma and rhinitis, amphiregulin, histamine inducing airway remodeling through EGF receptor ligand release, expression and function of the epidermal growth factor receptor, oxidized IL-33 signaling via RAGE/EGFR driving COPD phenotype, myeloid cell subsets classification, TNF-α sensitizing lung fibroblasts to Fas-induced apoptosis, antagonistic effects of TNF-α on TGF-β signaling, increased cell surface Fas expression sensitizing lung fibroblasts to apoptosis, IL-33-induced neutrophilic inflammation and NETosis in rhinovirus-triggered asthma, DP1 activation reversing age-related hypertension, prostaglandin D2-D prostanoid 1 signaling reducing intestinal permeability, activated prostaglandin D2 receptors enhancing neutrophil recruitment, pharmacologic profile of OC000459, hematopoietic prostaglandin D synthase inhibitor PK007, effect of fluticasone propionate on virus-induced airways inflammation, anti-TIM3 antibody promoting antitumor immunity, PAG1 limiting allergen-induced type 2 inflammation, HMGB1 amplifying ILC2-induced type-2 inflammation, PGD2/DP2 receptor activation promoting severe viral bronchiolitis, maternal diet modulating infant microbiome and immunity to respiratory infection, plasmacytoid dendritic cells protecting from viral bronchiolitis through T reg expansion.

DiffuSphere™, a microsphere designed for precise drug delivery to target tissues, has shown efficacy in treating eosinophilic esophagitis and osteoarthritis with a single administration lasting over six months. The technology, which minimizes systemic drug exposure, has demonstrated versatility across various drug classes and applications, including pain, infectious diseases, eye diseases, and cancers.

Regeneron and Sanofi's Dupixent gains FDA approval for COPD, becoming the first targeted therapy for the condition, with a Phase 3 trial showing reduced exacerbations and improved lung function.

FDA expands DUPIXENT use for COPD, offering new treatment options for patients. COPD affects 44 million in 7MM, with cases expected to rise. DUPIXENT targets IL-4 and IL-13 pathways, reducing exacerbations and improving lung function.

Viatris (VTRS) to report Q3 results on Nov. 7, 2024; Zacks Consensus Estimate for revenues at $3.68B and earnings at $0.68/share. Developed Markets expected to contribute $2.2B, Emerging Markets $567M, JANZ $396M, and Greater China $562M. Brand business growth in Emerging Markets, JANZ, and Greater China offset by unfavorable dynamics in North America and price regulations in Japan/Australia. Generics business improved due to new product launches and strong performance in Europe. Operating expenses likely increased due to SG&A investments and R&D progress.

Cipla's Goa manufacturing facility, cleared after regulatory hurdles, paves the way for the launch of key oncology drug Abraxane, expected to be a $120 million opportunity. Brokerages upgrade Cipla's outlook, anticipating significant revenue contributions from the Goa unit and future drug launches, driving stock gains.

Cipla faces delays in launching key drugs Advair and Abraxane due to regulatory hurdles, projecting a mid-FY26 launch for Advair and pending clearance for Abraxane's Goa facility. Competitors gaining ground could impact market share and revenue potential.